KM
SPPI

Kalos Management’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Kalos Management’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200
Closed -$150 – 403
2023
Q1 		$150 Buy
+200
New +$146 ﹤0.01% 395
2015
Q4 		– Hold
0
– – – 456

Other funds holding SPPI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NYLIM
New York Life Investment Management New York $11.8B AUM 23.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kalos Management's SPPI Position: Q2 2023 in Review

Kalos Management sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q2 2023, closing a stake of 200 shares — an estimated $150 sold.

Kalos Management first reported a position in SPPI in Q1 2023 and held it in 1 quarter. The position peaked at $150 in Q1 2023. 78 funds tracked by Wall St. Rank hold SPPI as of Q2 2023.

  • Kalos Management reported no remaining Spectrum Pharmaceuticals Inc position as of Q2 2023 after selling out during the quarter.
  • Kalos Management sold 200 Spectrum Pharmaceuticals Inc shares in Q2 2023, an estimated $150.
  • Kalos Management first reported a position in Spectrum Pharmaceuticals Inc in Q1 2023 and held it in 1 quarter.
  • Kalos Management's Spectrum Pharmaceuticals Inc position peaked at $150 in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q2 2023.

Based on Kalos Management's 13F filing for Q2 2023, filed 9 Aug 2023.